CBT, lisdexamfetamine, second-generation antidepressants, and topiramate deemed effective
FRIDAY, July 1, 2016 (HealthDay News) — Patients struggling with binge-eating disorder have several efficacious treatment options available, according to a review published online June 28 in the Annals of Internal Medicine.
Kimberly Brownley, Ph.D., an associate professor with the University of North Carolina Center of Excellence for Eating Disorders in Chapel Hill, and colleagues looked at 34 different clinical trials that tested potential treatments for binge-eating disorder.
The researchers found that patients who took part in therapist-led cognitive-behavioral therapy were about five times more likely to abstain from binge eating than those not receiving the therapy. Patients taking lisdexamfetamine were more than 2.5 times more likely to refrain from binge eating. Patients taking second-generation antidepressants were 67 percent more likely to curtail binge eating. The team found that other forms of cognitive behavioral therapy and topiramate also increased abstinence and reduced binge-eating frequency and related psychopathology.
“Cognitive behavioral therapy, lisdexamfetamine, second-generation antidepressants, and topiramate reduced binge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating disorder,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Shire, which manufactures lisdexamfetamine.
Full Text
Editorial (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
